Because Genentech is a leading developer of cancer therapies, some doctors also fear that the company's pricing plans for Avastin - around $8,800 a month - may encourage other companies to charge more for their own oncology drugs.
The biggest profit center for investment banks is the hefty fees they charge for underwriting stock offerings and giving financial advice, and analysts put those profits at risk if they publish negative conclusions about the companies that pay the fees.